G0138 Intravenous cipaglucosidase alfa-atga
Also known as: IV Ambreya, enzyme replacement therapy
Intravenous infusion of cipaglucosidase alfa-atgamrasidase (Ambreya), an enzyme replacement therapy for Pompe disease, including preparation and administration.
Clinical Context
Specialized enzyme replacement therapy for Pompe disease (glycogen storage disease Type II). Administered as IV infusion; requires rheumatology or neurology specialist oversight.
RVU Breakdown
| Work RVU | 0.21 |
| Practice Expense RVU | 5.62 |
| Malpractice RVU | 0.05 |
| Total RVU | 5.88 |
Est. Medicare Payment
National estimate based on 2026 CMS PFS Conversion Factor ($33.40). Actual payment varies by locality (GPCI adjustment).
Specialties
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.